How Piramal Pharma’s Integrated ESG Strategy is Reshaping the Future of ESG Investing
The pharmaceutical sector, long scrutinized for its environmental footprint and ethical practices, is undergoing a transformative shift. Investors are increasingly prioritizing companies that align with global sustainability goals, seeking long-term value creation through measurable ESG (Environmental, Social, and Governance) performance. Among these, Piramal Pharma Limited (PPL) stands out as a trailblazer. Its 2025 Integrated ESG Strategy, anchored in the vision of “Innovating Responsibly. Growing Sustainably,” positions the company as a leader in the contract development and manufacturing organization (CDMO) space. For investors, PPL’s approach offers a compelling case for sustainable, future-proof growth.
